Progressive Supranuclear Palsy (PSP) - Epidemiology Forecast - 2030 - ResearchAndMarkets.com

DUBLIN--()--The "Progressive Supranuclear Palsy (PSP) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Progressive supranuclear palsy in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Progressive supranuclear palsy Disease Understanding

Progressive Supranuclear Palsy (PSP) is an adult onset, progressive, sporadic neurodegenerative disease and an important cause of atypical Parkinsonism. The classic syndrome of PSP (Richardson's syndrome or RS) is characterized by postural instability and falls early in the disease course and by gaze dysfunction affecting the vertical eye movements more than the horizontal ones.

Progressive supranuclear palsy Epidemiology

The Progressive supranuclear palsy epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Progressive supranuclear palsy are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Progressive supranuclear palsy Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Prevalence of Progressive supranuclear palsy, Phenotype associated with Progressive supranuclear palsy, Gender specific Prevalence of Progressive supranuclear palsy, Comorbidities associated with Progressive supranuclear palsy) scenario of Progressive supranuclear palsy in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.

Report Scope

  • The report covers detailed overview of Progressive supranuclear palsy explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Progressive supranuclear palsy in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by prevalence of Progressive supranuclear palsy, phenotype associated with Progressive supranuclear palsy, gender specific prevalence of Progressive supranuclear palsy, comorbidities associated with Progressive supranuclear palsy

Key Topics Covered:

1 Key Insights

2 Executive Summary of Progressive Supranuclear Palsy

3 SWOT Analysis for Progressive Supranuclear Palsy

4 Progressive Supranuclear Palsy (PSP) Epidemiology Overview at a Glance

4.1 Epidemiology of Progressive Supranuclear Palsy (PSP) in 2017

4.2 Epidemiology of Progressive Supranuclear Palsy (PSP) in 2030

5 Disease Background and Overview: Progressive Supranuclear Palsy (PSP)

5.1 Introduction

5.2 Signs and symptoms

5.3 Phenotypes of Progressive Supranuclear Palsy

5.4 History

5.5 Associated risk factors

5.6 Genetics

5.7 Pathophysiology

5.8 PSP associated abnormalities

5.9 Clinical Presentation and Assessment

5.10 Clinical Diagnosis of Progressive Supranuclear Palsy: The Movement Disorder Society Criteria

5.11 PET Imaging as a Biomarker in Tauopathies

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 7MM Total Prevalent Patient Population of Progressive Supranuclear Palsy [PSP]

7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)

7.1 The United States

7.2 Europe

7.3 Japan

8 Treatment

8.1 Current symptomatic treatment

9 Unmet Needs

10 Appendix

10.1 Report Methodology

11 Capabilities

12 Disclaimer

13 About the Publisher

For more information about this report visit https://www.researchandmarkets.com/r/8eeiz2

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900